An Efficient Microwave-Assisted Synthesis of 3,5-Unsubstituted 4-Substituted-6-aryl-3,4-dihydropyridin-2(1*H*)-ones Derivatives

Shujiang Tu,* Xiaotong Zhu, Feng Shi, Jinpeng Zhang, Yan Zhang

Department of Chemistry, Xuzhou Normal University, Key Laboratory of Biotechnology on Medical Plant, Xuzhou; Jiangsu, 221009, P. R. China Received August 3, 2006



Small libraries of 3,5-unsubstituted 4-substituted-6-aryl-3,4-dihydropyridin-2(1H)-ones derivatives were synthesized from the condensation-products of aldehydes with Meldrum's acid, aromatic ketones and ammonium acetate using acetic acid as energy transferring-agent under microwave irradiation without catalyst. This method has the advantages of excellent yields (65–90%), short reaction time (5–10 min) and being environmentally friendly. It aimed to provide new series of potential biologically active compounds for biomedical screening.

J. Heterocyclic Chem., 44, 837 (2007).

INTRODUCTION

2-Pyridones play an important theoretical and practical role in heterocyclic chemistry [1]. The nucleus of 2-pyridone occurs widely in the structures of biologically important natural alkaloids [2]. Recently, some functionalized 2-pyridone derivatives are even found to exhibit interesting bioactivity and served as versatile synthetic intermediates in pharmaceutical and agrochemical research [3]. Because of their importance, the synthesis of these molecules containing 2(1H)-pyridone unit has attracted considerable attention [4].

As a member of the 2-pyridone family 4,6-diaryl-2pyridones are recognized as potent LTB₄ antagonists [5]. Numerous methods for the preparation of the 4,6-diaryl-2pyridone template have been reported many times in the literature, such as the synthesis of 3-substituted-2pyridone [6-8] derivatives (**A**) which are functionalized at the 3 and 4 position. In addition, slight modification of the 4,6-diaryl-2-pyridone nucleus was reported to afford a series of 3-unsubstituted 2-pyridone derivatives [5,9-11] (**B**) which provide new series of biologically active compounds.



Substituted six-membered lactams, 2-pyridones, and their 3,4-dihydro derivatives have also attracted considerable attention from synthetic organic chemists since these scaffolds are found in a wide variety of naturally occurring alkaloids [12] and compounds with these structural motifs have been shown to exhibit significant pharmacological properties [13], for example dihydro-2-pyridones have been applied as scaffolds to the construction of constrained amino acid [14]. However, little attention has been paid to the synthesis of 3,4dihydro-4,6-diaryl-2-pyridones which are unsubstituted on the 3- and 5-positions. And up to now, to the best of our knowledge, there are no reports on the synthesis of them. For the aim of offering a new series of candidates for bioactivity screening, herein we carried out the research on the synthesis of this new type of 2-pyridone through an efficient three-component reaction assisted by microwave irradiation (Scheme I).



RESULTS AND DISCUSSION

Initially, we explored the synthesis of **5b** (see Table 1) which was prepared from the condensation-product **3b** [15] (2 mmol), 3-nitroacetophenone (2 mmol) and ammonium acetate (1.0 g) with acetic acid (1.4 mL) as solvent by mechanical stirring. The reaction was performed at 100 °C under conventional heating by 7.5 h,

monitered by TLC, which gave the target product in 55% yield. However, under microwave irradiation at this condition (200 W) for 6 min, the yield was enhanced to 88%. The efficiency of microwave irradiation (MWI) in promoting the above reaction triggered us to apply it to accelerate the reaction and improve the reaction yields.

In this reaction, we use two kinds of representative arones: one contains electron-withdrawing group such as 3-nitroacetophenone, 2-chloroacetophenone and 2,4-dichloroacetophenone, the other comprises electron-contributing electronic nature of arone has significant influence on the reaction.

We supposed the mechanism of this reaction, which includes Michael addition, cyclization and the loss of acetone and carbon dioxide (Scheme II).

It is well known that the Michael addition is strongly affected by solvent and acid-base property besides the nature of reactant [16]. Therefore, we explored the reaction condition by changing the mass ratio of ammonium acetate and acetic acid. When the reaction was

Compound	Ar	R	Time (min)	Yield (%)	Mp (°C)
5a	3-NO ₂ C ₆ H ₄	$4-ClC_6H_4$	5	90	295.6-296.9
5b	$3-NO_2C_6H_4$	$4-BrC_6H_4$	6	88	205.0-206.0
5c	$3-NO_2C_6H_4$	2-ClC ₆ H ₄	8	85	182.6-183.8
5d	$3-NO_2C_6H_4$	2,4-Cl ₂ C ₆ H ₃	5	80	222.3-223.4
5e	$3-NO_2C_6H_4$	3,4-Cl ₂ C ₆ H ₃	6	82	256.3-257.0
5f	$3-NO_2C_6H_4$	$4-FC_6H_4$	5	90	232.2-233.2
5g	$3-NO_2C_6H_4$	$3-NO_2C_6H_4$	7	82	279.2-280.0
5h	$3-NO_2C_6H_4$	3,4-(OCH ₃) ₂ C ₆ H ₃	9	80	231.2-232.5
5i	$3-NO_2C_6H_4$	$4-CH_3C_6H_4$	9	75	183.0-184.0
5j	$3-NO_2C_6H_4$	3,4-OCH ₂ OC ₆ H ₃	7	85	204.5-205.2
5k	$3-NO_2C_6H_4$	$CH_3(CH_2)_3$	9	70	122.3-124.1
51	$3-NO_2C_6H_4$	thiophen-2-yl	9	80	142.0-144.0
5m	4-CH ₃ OC ₆ H ₄	$4-ClC_6H_4$	7	80	164.5-165.9
5n	$4-CH_3OC_6H_4$	$4-BrC_6H_4$	8	75	173.6-174.8
50	$4-CH_3OC_6H_4$	2,4-Cl ₂ C ₆ H ₃	9	70	219.0-220.0
5р	$4-CH_3OC_6H_4$	3,4-Cl ₂ C ₆ H ₃	7	68	153.4-154.5
5q	$4-CH_3OC_6H_4$	3,4-OCH ₂ OC ₆ H ₃	10	65	183.9-184.7
5r	$4-NO_2C_6H_4$	$4-BrC_6H_4$	6	81	214.8-215.5
5s	$4-NO_2C_6H_4$	$4-ClC_6H_4$	7	82	199.9-201.2
5t	$2,4-Cl_2C_6H_3$	$4-ClC_6H_4$	9	79	178.0-179.0
5u	2-ClC ₆ H ₄	$4-BrC_6H_4$	8	80	>300

 Table 1

 Synthesis of 3,4-Dihydropyridine-2(1H)-ones Derivatives 5

Note: All reactions were performed in 1.4 mL acetic acid

Table 2

Compound	Ar	R	Time (min)	Yield (%)	Mp (°C) (lit.)
6a	$3-NO_2C_6H_4$	2-ClC ₆ H ₄	4	89	225.0-226.1
6b	$3-NO_2C_6H_4$	$4-CH_3C_6H_4$	5	86	258.7-263.4
6c	4-CH ₃ OC ₆ H ₄	$4-BrC_6H_4$	3	91	164.1-165.3 (163.9-165.0)18
6d	$2,4-Cl_2C_6H_3$	$2,4-Cl_2C_6H_3$	6	90	202.9-204.7 (203.9-204.8)18

group such as 4-methoxyacetophenone. Table 1 showed that the electrophilic arone could react with a wide range of condensation-products of Meldrum's acid 2 with various aldehydes 1 (including aromatic, aliphatic and hetero cyclic aldehydes) with higher yields (70–90%) in shorter reaction time (5–9 min). when the arone with electron-donating group was used, the yields were relatively lower (65–80%) and the reaction time was longer (7–10 min). The results demonstrated that the

processed without acetic acid, the compound **6** [17] of 2,4,6-triarylpyridine derivative was obtained instead of compound **5** (Scheme III). So, the solvents play crucial role in this reaction. The initial results are summarized in Table 2.

It may be generated by a series of addition, elimination, and then cyclization, dehydration and aromatization procedure (Scheme IV). While a small quantity of acetic acid was added as solvent, the mixture of 5 and 6 was





obtained. In order to improve the yields of **5**, we tested various ratios and found when the mass ratio of ammonium acetate and acetic acid is 3:4 the reaction gave the best result.



All the products were characterized by IR and ¹H NMR analysis. And the elemental analyses of these compounds are in agreement with their structures. The structure of **5f** was also confirmed by X-ray diffraction study [18] (Figure 1).

In summary, we have disclosed a new method to synthesize 4-substituted-6-aryl-3,4-dihydropyridin-2(1H) -ones by multi-components of commercially available reagents under microwave irradiation. This method has the advantages of shorter reaction time, higher yields, easy work-up procedure and being environmentally friendly. Most importantly, a series of new compounds synthesized on the basis of 4,6-diaryl-3,4-dihydropyridi



Figure 1. The structure of 5f.

ne-2(1H)-one skeleton may lead to new candidates for medicinal application through bioactivity screening and this work is in progress in our laboratory.

EXPERIMENTAL

General Procedure for the Reaction of 5-arylidene-2,2dimethyl-1,3-dioxane-4,6-dione (3). All reactions were performed in a monomodal Emrys^{TM} Creator from Personal Chemistry, Uppsala, Sweden. Typically, in a 10-mL Emrys^{TM} reaction vial, the appropriate aldehyde 1 (5.0 mmol) and the little excessive Meldrum's acid (6.0 mmol) in ethanol (2.0 mL) were mixed and then capped. The mixture was irradiated at 150 W at 80 °C for 3–7 min (the reaction was monitored by TLC). The reaction mixture was cooled to room temperature and filtered to afford the crude products. The crude products were purified by recrystallization from ethanol.

General Procedure for the Reaction of 4-Substituted-6aryl-3,4-dihydropyridin-2(1*H*)-ones (5). All reactions were performed in a monomodal EmrysTM Creator from Personal Chemistry, Uppsala, Sweden. Typically, in a 10-mL EmrysTM reaction vial, starting-material 3 (2 mmol), aromatic ketone 4 (2 mmol) and ammonium acetate (1.0 g) in acetic acid (1.4 mL) were mixed and then capped. The mixture was irradiated at 200 W at 100 °C for a given time (the reaction was monitored by TLC). The reaction mixture was cooled to room temperature and poured into 50 mL water, filtered to give the crude product, which was further purified by recrystallization from DMF.

4-(4-Chlorophenyl)-6-(3-nitrophenyl)-3,4-dihydropyridin-2 (1*H***)-one (5a). This compound was obtained according to above general procedure; ir (potassium bromide): 3232, 3123, 1677, 1626, 1528, 1469, 1406, 1350, 1088, 1011, 823, 800, 780 cm⁻¹; ¹H nmr (DMSO-d₆): \delta 9.94 (s, 1H, NH), 8.37 (s, 1H, ArH), 8.22 (d, 1H, J = 8.4 Hz, ArH), 8.04 (d, 1H, J = 7.6 Hz, ArH), 7.69 (t, 1H, J = 8.0 Hz, ArH), 7.40 (d, 2H, J = 8.4 Hz, ArH), 7.37 (d, 2H, J = 8.4 Hz, ArH), 5.80 (d, 1H, J = 4.4 Hz, ⁵CH), 4.03–3.98 (m, 1H, ⁴CH), 2.77 (dd, 1H, J_1 = 16.0, J_2 = 6.8 Hz, ³CH₂), 2.56 (dd, 1H, J_1 = 16.0 Hz, J_2 = 8.0 Hz, ³CH₂).** *Anal.* **Calcd. for C₁₇H₁₃ClN₂O₃: C, 62.11; H, 3.99; N, 8.52. Found: C, 62.25; H, 3.86; N, 8.47.**

4-(4-Bromophenyl)-6-(3-nitrophenyl)-3,4-dihydropyridin-2 (**1***H*)-one (**5**b). ir (potassium bromide): 3195, 3093, 1668, 1628, 1572, 1522, 1401, 1346, 1166, 1009, 825, 803, 790 cm⁻¹; ¹H nmr (DMSO-d₆): δ 9.96 (s, 1H, NH), 7.32 (s, 1H, ArH), 8.22 (d, 1H, *J* = 8.0 Hz, ArH), 8.04 (d, 1H, *J* = 8.4 Hz, ArH), 7.70 (t, 1H, *J* = 8.0 Hz, ArH), 7.55 (d, 2H, *J* = 8.4 Hz, ArH), 7.31 (d, 2H, *J* = 8.4 Hz, ArH), 5.82 (d, 1H, J = 4.4 Hz, ⁵CH), 4.01–3.96 (m, 1H, ⁴CH), 2.76 (dd, 1H, $J_1 = 16.0$, $J_2 = 6.4$ Hz, ³CH₂), 2.51 (dd, 1H, $J_1 = 16.0$ Hz, $J_2 = 8.0$ Hz, ³CH₂). *Anal.* Calcd. for C₁₇H₁₃BrN₂O₃: C, 54.71; H, 3.51; N, 7.51. Found: C, 54.62; H, 3.43; N, 7.41.

4-(2-Chlorophenyl)-6-(3-nitrophenyl)-3,4-dihydropyridin-2 (1*H***)-one (5c). ir (potassium bromide): 3188, 3072, 2921, 1695, 1618, 1577, 1528, 1474, 1411, 1349, 1258, 1162, 1041, 809, 790, 740 cm⁻¹; ¹H nmr (DMSO-d₆): \delta 10.01 (s, 1H, NH), 8.38 (s, 1H, ArH), 8.23 (d, 1H,** *J* **= 8.0 Hz, ArH), 8.04 (d, 1H,** *J* **= 8.0 Hz, ArH), 7.70 (t, 1H,** *J* **= 8.0 Hz, ArH), 7.51 (d, 1H,** *J* **= 7.8 Hz, ArH), 7.70 (t, 1H,** *J* **= 8.0 Hz, ArH), 7.51 (d, 1H,** *J* **= 7.8 Hz, ArH), 7.41–7.30 (m, 3H, ArH), 5.79 (d, 1H,** *J* **= 4.8 Hz, ⁵CH), 4.33–4.28 (m, 1H, ⁴CH), 2.84 (dd, 1H,** *J***₁ = 16.0,** *J***₂ = 7.2 Hz, ³CH₂), 2.54 (dd, 1H,** *J***₁ = 15.6 Hz,** *J***₂ = 6.4 Hz, ³CH₂).** *Anal.* **Calcd. for C₁₇H₁₃ClN₂O₃: C, 62.11; H, 3.99; N, 8.52. Found: C, 62.24; H, 4.02; N, 8.56.**

4-(2,4-Dichlorophenyl)-6-(3-nitrophenyl)-3,4-dihydropyridin-2(1*H***)-one (5d).** ir (potassium bromide): 3228, 3107, 1682, 1625, 1530, 1463, 1342, 1254, 1094, 1041, 897, 805, 784, 696 cm⁻¹; ¹H nmr (DMSO-d₆): δ 10.06 (s, 1H, NH), 8.38 (s, 1H, ArH), 8.24 (d, 1H, *J* = 8.0 Hz, ArH), 8.06 (d, 1H, *J* = 8.4 Hz, ArH), 8.39 (t, 1H, *J* = 8.0 Hz, ArH), 8.05 (d, 1H, *J* = 8.0 Hz, ArH), 7.57–7.39 (m, 2H, ArH), 5.82 (d, 1H, *J* = 4.4 Hz, ⁵CH), 4.33–4.28 (m, 1H, ⁴CH), 2.82 (dd, 1H, *J*₁ = 16.0, *J*₂ = 7.2 Hz, ³CH₂), 2.58 (dd, 1H, *J*₁ = 15.8 Hz, *J*₂ = 8.0 Hz, ³CH₂). *Anal.* Calcd. for C₁₇H₁₂Cl₂N₂O₃: C, 56.22; H, 3.33; N, 7.71. Found: C, 56.33; H, 3.18; N, 7.78.

4-(3,4-Dichlorophenyl)-6-(3-nitrophenyl)-3,4-dihydropyridin-2(1*H***)-one (5e). ir (potassium bromide): 3231, 3099, 1695, 1630, 1521, 1465, 1353, 1285, 1138, 1030, 971, 927, 810, 787 cm⁻¹; ¹H nmr (DMSO-d₆): \delta 9.96 (s, 1H, NH), 8.37 (s, 1H, ArH), 8.22 (dd, 1H, J_1 = 8.4 Hz, J_2 = 1.2 Hz, ArH), 8.04 (d, 1H, J = 8.4 Hz, ArH), 7.69 (t, 1H, J = 8.0 Hz, ArH), 7.63 (s, 1H, ArH), 7.61 (d, 1H, J = 8.0 Hz, ArH), 7.35 (dd, 1H, J_1 = 8.4 Hz, J_2 = 2.0 Hz, ArH), 5.81 (d, 1H, J = 4.0 Hz, ⁵CH), 4.06–4.01 (m, 1H, ⁴CH), 2.77 (dd, 1H, J_1 = 16.6 Hz, J_2 = 7.4 Hz, ³CH₂), 2.60 (dd, 1H, J_1 = 15.8 Hz, J_2 = 8.8 Hz, ³CH₂). Anal. Calcd. for C₁₇H₁₂Cl₂N₂O₃: C, 56.22; H, 3.33; N, 7.71. Found: C, 56.26; H, 3.36; N, 7.76.**

4-(4-Flurophenyl)-6-(3-nitrophenyl)-3,4-dihydropyridin-2(1*H***)-one (5f). ir (potassium bromide): 3233, 3124, 1685, 1648, 1530, 1469, 1352, 1218, 1162, 827, 775, 693 cm⁻¹; ¹H nmr (DMSO-d₆): \delta 9.94 (s, 1H, NH), 8.37 (s, 1H, ArH), 8.22 (d, 1H,** *J* **= 8.0 Hz, ArH), 8.04 (d, 1H,** *J* **= 7.2 Hz, ArH), 7.69 (t, 1H,** *J* **= 7.8 Hz, ArH), 7.39–7.35 (m, 2H, ArH), 7.21–7.16 (m, 2H, ArH), 5.81 (d, 1H,** *J* **= 4.4 Hz, ⁵CH), 4.02–3.98 (m, 1H, ⁴CH), 2.76 (dd, 1H,** *J***₁ = 15.6,** *J***₂ = 6.8 Hz, ³CH₂), 2.56 (dd, 1H,** *J***₁ = 15.6 Hz,** *J***₂ = 8.4 Hz, ³CH₂).** *Anal.* **Calcd. for C₁₇H₁₃FN₂O₃: C, 65.38; H, 4.20; N, 8.97. Found: C, 65.45; H, 4.32; N, 8.78.**

4-(3-Nitrophenyl)-6-(3-nitrophenyl)-3,4-dihydropyridin-2(1*H***)-one (5g). ir (potassium bromide): 3230, 3081, 1686, 1643, 1577, 1521, 1352, 1102, 805, 790 cm⁻¹; ¹H nmr (DMSO-d₆): \delta 10.03 (s, 1H, NH), 8.39 (s, 1H, ArH), 8.23 (dd, 1H, J_1 = 8.0 Hz, J_2 = 1.6 Hz, ArH), 8.20 (s, 1H, ArH), 8.14 (dd, 1H, J_1 = 8.0 Hz, J_2 = 1.6 Hz, ArH), 8.05 (d, 1H, J = 8.0 Hz, ArH), 7.84 (d, 1H, J = 7.6 Hz, ArH), 7.73–7.65 (m, 2H, ArH), 5.87 (d, 1H, J = 3.6 Hz, J_2 = 6.8 Hz, {}^{3}CH₂), 2.66 (dd, 1H, J_1 = 15.8 Hz, J_2 = 8.8 Hz, {}^{3}CH₂).** *Anal.* **Calcd. for C₁₇H₁₃N₃O₅: C, 60.18; H, 3.86; N, 12.38. Found: C, 60.34; H, 3.79; N, 12.45.**

4-(3,4-Dimethoxyphenyl)-6-(3-nitrophenyl)-3,4-dihydropyridin-2(1H)-one (5h). ir (potassium bromide): 3250, 3099, 2935, 2835, 1683, 1609, 1593, 1523, 1416, 1352, 1262, 1138, 1031, 916, 800, 787, 698 cm⁻¹; ¹H nmr (DMSO-d₆): δ 9.87 (s, 1H, NH), 8.35 (s, 1H, ArH), 8.21 (dd, 1H, $J_1 = 8.0$ Hz, $J_2 = 1.4$ Hz, ArH), 8.03 (d, 1H, J = 8.4 Hz, ArH), 7.69 (t, 1H, J = 8.0 Hz, ArH), 6.95-6.91 (m, 1H, ArH), 6.90 (s, 1H, ArH), 6.83 (dd, 1H, $J_1 = 8.4$ Hz, $J_2 = 2.0$ Hz, ArH), 5.79 (d, 1H, J = 4.4 Hz, ⁵CH), 3.96–3.87 (m, 1H, ⁴CH), 3.75 (s, 3H, OCH₃), 3.73 (s, 3H, OCH₃), 2.72 (dd, 1H, $J_1 = 15.8$ Hz, $J_2 = 7.0$ Hz, ³CH₂), 2.58 (dd, 1H, $J_1 = 15.8$ Hz, $J_2 = 8.8$ Hz, ³CH₂). Anal. Calcd. for C₁₉H₁₈N₂O₅: C, 64.40; H, 5.12; N, 7.91. Found: C, 64.51; H, 5.09; N, 7.85.

4-(4-Methylphenyl)-6-(3-nitrophenyl)-3,4-dihydropyridin-2(1*H***)-one (5i). ir (potassium bromide): 3234, 3125, 1682, 1651, 1611, 1530, 1471, 1349, 810, 781 cm⁻¹; ¹H nmr (DMSO-d₆): \delta 9.88 (s, 1H, NH), 8.35 (s, 1H, ArH), 8.21 (d, 1H,** *J* **= 8.4 Hz, ArH), 8.03 (d, 1H,** *J* **= 8.0 Hz, ArH), 7.68 (t, 1H,** *J* **= 7.6 Hz, ArH), 7.21 (d, 2H,** *J* **= 7.2 Hz, ArH), 7.15 (d, 2H,** *J* **= 7.2 Hz, ArH), 5.79 (d, 1H,** *J* **= 4.4 Hz, ⁵CH), 3.93–3.88 (m, 1H, ⁴CH), 2.74 (dd, 1H,** *J***₁ = 16.0 Hz,** *J***₂ = 5.4 Hz, ³CH₂), 2.53 (dd, 1H,** *J***₁ = 16.0 Hz,** *J***₂ = 6.4 Hz, ³CH₂), 2.28 (s, 3H, CH₃).** *Anal.* **Calcd. for C₁₈H₁₆N₂O₃: C, 70.12; H, 5.23; N, 9.09. Found: C, 70.26; H, 5.14; N, 9.01.**

4-(3,4-Methylenedioxylphenyl)-6-(3-nitrophenyl)-3,4dihydropyridin-2(1H)-one (5j). ir (potassium bromide): 3199, 3095, 2890, 1668, 1608, 1520, 1440, 1344, 1242, 1039, 937, 806, 792 cm⁻¹; ¹H nmr (DMSO-d₆): δ 9.87 (s, 1H, NH), 8.35 (s, 1H, ArH), 8.21 (d, 1H, J = 8.4 Hz, ArH), 8.02 (d, 1H, J = 8.0 Hz, ArH), 7.71 (t, 1H, J = 8.0 Hz, ArH), 6.92–6.86 (m, 2H, ArH), 6.78 (d, 1H, J = 8.0 Hz, ArH), 5.98 (s, 2H, OCH₂O), 5.78 (d, 1H, J = 4.8 Hz, ⁵CH), 3.94–3.86 (m, 1H, ⁴CH), 2.68 (dd, 1H, $J_1 = 16.0$ Hz, $J_2 = 6.8$ Hz, ³CH₂), 2.51 (dd, 1H, $J_1 = 15.8$ Hz, $J_2 = 8.0$ Hz, ³CH₂). *Anal.* Calcd. for C₁₈H₁₄N₂O₅: C, 63.90; H, 4.17; N, 8.28. Found: C, 64.01; H, 4.12; N, 8.33.

4-Butyl-6-(3-nitrophenyl)-3,4-dihydropyridin-2(1*H***)-one (5**k). ir (potassium bromide): 3231, 3098, 2950, 2892, 1681, 1625, 1522, 1467, 1352, 1105, 812, 791, 709 cm⁻¹; ¹H nmr (DMSO-d₆): δ 9.70 (s, 1H, NH), 8.29 (s, 1H, ArH), 8.18 (d, 1H, *J* = 8.0 Hz, ArH), 7.97 (d, 1H, *J* = 8.0 Hz, ArH), 7.67 (t, 1H, *J* = 8.0 Hz, ArH), 5.64 (d, 1H, *J* = 3.6 Hz, ⁵CH), 2.59–2.55 (m, 1H, ⁴CH), 2.48 (dd, 1H, *J*₁ = 17.0 Hz, *J*₂ = 7.4 Hz, ³CH₂), 2.21 (dd, 1H, *J*₁ = 15.6 Hz, *J*₂ = 9.2 Hz, ³CH₂), 1.46–1.33 (m, 6H, 3 × CH₂), 0.91 (t, 3H, *J* = 7.0 Hz, CH₃). *Anal.* Calcd. for C₁₅H₁₈N₂O₃: C, 65.68; H, 6.61; N, 10.21. Found: C, 65.79; H, 6.52; N, 10.13.

4-(2-Thiofuran)-6-(3-nitrophenyl)-3,4-dihydropyridin-2(1*H***)-one (5). ir (potassium bromide): 3215, 3089, 1697, 1654, 1524, 1471, 1416, 1349, 1282, 1050, 798, 700 cm⁻¹; ¹H nmr (DMSO-d₆): \delta 9.94 (s, 1H, NH), 8.35 (s, 1H, ArH), 8.23 (d, 1H,** *J* **= 7.6 Hz, ArH), 8.03 (d, 1H,** *J* **= 8.0 Hz, ArH), 7.70 (t, 1H,** *J* **= 8.0 Hz, ArH), 7.40 (dd, 1H,** *J***₁ = 5.0 Hz,** *J***₂ = 1.0 Hz, thiophen-2-yl-H), 7.01–6.99 (m, 2H, thiophen-2-yl-H), 5.87 (d, 1H,** *J* **= 4.8 Hz, ⁵CH), 4.28–4.21 (m, 1H, ⁴CH), 2.87 (dd, 1H,** *J***₁ = 16.0 Hz,** *J***₂ = 6.8 Hz, ³CH₂), 2.61 (dd, 1H,** *J***₁ = 15.8 Hz,** *J***₂ = 6.8 Hz, ³CH₂), 2.61 (dd, 1H,** *J***₁ = 15.8 Hz,** *J***₂ = 6.8 Hz, ³CH₂), 3.068. Found: C, 60.08; H, 3.96; N, 9.25; S, 10.62.**

4-(4-Chlorophenyl)-6-(4-methoxyphenyl)-3,4-dihydropyridin-2(1*H***)-one (5m). ir (potassium bromide): 3220, 3101, 1671, 1652, 1609, 1518, 1472, 1373, 1245, 1190, 819 cm⁻¹; ¹H nmr (DMSO-d₆): \delta 9.60 (s, 1H, NH), 7.49 (d, 1H,** *J* **= 8.8 Hz, ArH), 7.39 (d, 1H,** *J* **= 8.4 Hz, ArH), 7.32 (d, 1H,** *J* **= 8.4 Hz, ArH), 6.93 (d, 1H,** *J* **= 8.8 Hz, ArH), 5.44 (d, 1H,** *J* **= 4.4 Hz, ⁵CH), 3.93–3.88 (m, 1H, ⁴CH), 3.76 (s, 3H, OCH₃), 2.71 (dd, 1H,** *J***₁ = 16.0 Hz,** *J***₂ = 6.8 Hz, ³CH₂), 2.48 (dd, 1H,** *J***₁ = 15.2 Hz,** **4-(4-Bromophenyl)-6-(4-methoxyphenyl)-3,4-dihydropyridin-2(1***H***)-one (5n). ir (potassium bromide): 3222, 3103, 1673, 1655, 1609, 1515, 1488, 1372, 1246, 1188, 1010, 824 cm⁻¹; ¹H nmr (DMSO-d₆): \delta 9.59 (s, 1H, NH), 7.53 (d, 2H,** *J* **= 8.4 Hz, ArH), 7.50 (d, 2H,** *J* **= 8.8 Hz, ArH), 7.28 (d, 2H,** *J* **= 8.4 Hz, ArH), 6.94 (d, 2H,** *J* **= 8.8 Hz, ArH), 5.44 (d, 1H,** *J* **= 4.4 Hz, ⁵CH), 3.92–3.87 (m, 1H, ⁴CH), 3.78 (s, 3H, OCH₃), 2.72 (dd, 1H,** *J***₁ = 15.8 Hz,** *J***₂ = 7.0 Hz, ³CH₂), 2.49 (dd, 1H,** *J***₁ = 16.0 Hz,** *J***₂ = 8.0 Hz, ³CH₂).** *Anal.* **Calcd. for C₁₈H₁₆BrNO₂: C, 60.35; H, 4.50; N, 3.91. Found: C, 60.34; H, 4.52; N, 3.40.**

4-(2,4-Dichlorophenyl)-6-(4-methoxyphenyl)-3,4-dihydropyridin-2(1*H***)-one (50). ir (potassium bromide): 3230, 3113, 3071, 1684, 1607, 1515, 1455, 1378, 1252, 1179, 1091, 1043, 956, 831 cm⁻¹; ¹H nmr (DMSO-d₆): \delta 9.72 (s, 1H, NH), 7.55-7.50 (m, 3H, ArH), 7.39 (dd, 1H, J_1 = 8.4 Hz, J_2 = 2.4 Hz, ArH), 7.33 (s, 1H, ArH), 6.95 (d, 1H, J = 8.8 Hz, ArH), 5.46 (d, 1H, J = 4.8 Hz, ⁵CH), 4.22–4.17 (m, 1H, ⁴CH), 3.81 (s, 3H, OCH₃), 2.81 (dd, 1H, J_1 = 15.8 Hz, J_2 = 7.0 Hz, ³CH₂), 2.50 (dd, 1H, J_1 = 16.0 Hz, J_2 = 8.8 Hz, ³CH₂).** *Anal.* **Calcd. for C₁₈H₁₅Cl₂NO₂: C, 62.08; H, 4.34; N, 4.02. Found: C, 62.12; H, 4.36; N, 4.12.**

4-(3,4-Dichlorophenyl)-6-(4-methoxyphenyl)-3,4-dihydropyridin-2(1*H***)-one (5**p). ir (potassium bromide): 3235, 3112, 2965, 2902, 1685, 1609, 1513, 1459, 1369, 1242, 1180, 1033, 961, 820 cm⁻¹; ¹H nmr (DMSO-d₆): δ 9.64 (s, 1H, NH), 7.60 (d, 2H, *J* = 8.4 Hz, ArH), 7.49 (d, 1H, *J* = 8.4 Hz, ArH), 7.31 (dd, 1H, *J*₁ = 8.4 Hz, ArH), 7.49 (d, 1H, *J* = 8.4 Hz, ArH), 7.31 (dd, 1H, *J*₁ = 8.4 Hz, *J*₂ = 2.0 Hz, ArH), 6.93 (d, 2H, *J* = 8.8 Hz, ArH), 5.45 (d, 1H, *J* = 4.4 Hz, ⁵CH), 3.96–3.91 (m, 1H, ⁴CH), 3.76 (s, 3H, OCH₃), 2.72 (dd, 1H, *J*₁ = 16.0 Hz, *J*₂ = 6.8 Hz, ³CH₂), 2.52 (dd, 1H, *J*₁ = 16.0 Hz, *J*₂ = 8.0 Hz, ³CH₂). *Anal.* Calcd. for C₁₈H₁₅Cl₂NO₂: C, 62.08; H, 4.34; N, 4.02. Found: C, 62.16; H, 4.31; N, 4.00.

4-(3,4-Methylenedioxylphenyl)-6-(4-methoxyphenyl)-3,4dihydropyridin-2(1*H***)-one (5**q). ir (potassium bromide): 3227, 3105, 2887, 2840, 1673, 1609, 1576, 1485, 1368, 1245, 1190, 1038, 932, 822 cm⁻¹; ¹H nmr (DMSO-d₆): δ 9.51 (s, 1H, NH), 7.50 (d, 2H, *J* = 8.8 Hz, ArH), 6.94 (d, 2H, *J* = 8.8 Hz, ArH), 6.86 (d, 2H, *J* = 8.8 Hz, ArH), 6.77 (d, 1H, *J* = 8.4 Hz, ArH), 5.98 (s, 2H, OCH₂O), 5.42 (d, 1H, *J* = 4.4 Hz, ⁵CH), 3.84–3.79 (m, 1H, ⁴CH), 3.78 (s, 3H, OCH₃), 2.68 (dd, 1H, *J*₁ = 16.0 Hz, *J*₂ = 6.8 Hz, ³CH₂), 2.48 (dd, 1H, *J*₁ = 16.0 Hz, *J*₂ = 7.2 Hz, ³CH₂). *Anal.* Calcd. for C₁₉H₁₇NO₄: C, 70.58; H, 5.30; N, 4.33. Found: C, 70.49; H, 5.42; N, 4.29.

4-(4-Bromophenyl)-6-(4-nitrophenyl)-3,4-dihydropyridin-2(1*H***)-one (5r). ir (potassium bromide): 3237, 3126, 3078, 2902, 1679, 1611, 1598, 1513, 1380, 1226, 1158, 1067, 749 cm⁻¹; ¹H nmr (DMSO-d₆): \delta 9.93 (s, 1H, NH), 8.23 (d, 2H,** *J* **= 8.8 Hz, ArH), 7.84 (d, 2H,** *J* **= 8.8 Hz, ArH), 7.55 (d, 2H,** *J* **= 8.0 Hz, ArH), 7.30 (d, 2H,** *J* **= 8.0 Hz, ArH), 5.86 (d, 1H,** *J* **= 4.8 Hz, ⁵CH), 4.03–3.98 (m, 1H, ⁴CH), 2.76 (dd, 1H,** *J***₁ = 15.6 Hz,** *J***₂ = 6.8 Hz, ³CH₂), 2.55 (dd, 1H,** *J***₁ = 16.0 Hz,** *J***₂ = 8.4 Hz, ³CH₂).** *Anal.* **Calcd. for C₁₇H₁₃BrN₂O₃: C, 54.71; H, 3.51; N, 7.51. Found: C, 54.83; H, 3.48; N, 7.55.**

4-(4-Chlorophenyl)-6-(4-nitrophenyl)-3,4-dihydropyridin-2(1*H***)-one (5s). ir (potassium bromide): 3228, 3111, 2885, 2837, 1683, 1606, 1598, 1519, 1492, 1346, 1089, 823, 750 cm⁻¹; ¹H nmr (DMSO-d₆): \delta 9.93 (s, 1H, NH), 8.24 (d, 2H,** *J* **= 8.8 Hz, ArH), 7.85 (d, 2H,** *J* **= 8.8 Hz, ArH), 7.42 (d, 2H,** *J* **= 4.4 Hz, ArH), 7.36 (d, 2H,** *J* **= 8.4 Hz, ArH), 5.87 (d, 1H,** *J* **= 4.4 Hz, ⁵CH), 4.05–3.40 (m, 1H, ⁴CH), 2.76 (dd, 1H,** *J***₁ = 16.0 Hz,** *J***₂ = 7.2 Hz, ³CH₂), 2.56 (dd, 1H,** *J***₁ = 15.6 Hz,** *J***₂ = 8.4 Hz, ³CH₂).** Anal. Calcd. for $C_{17}H_{13}CIN_2O_3$: C, 62.11; H, 3.99; N, 8.52. Found: C, 62.19; H, 4.03; N, 8.57.

4-(4-Chlorophenyl)-6-(2,4-dichlorophenyl)-3,4-dihydropyridin-2(1*H***)-one (5t). ir (potassium bromide): 3185, 3086, 2909, 2846, 1681, 1612, 1587, 1472, 1376, 1298, 1096, 994, 829, 794 cm⁻¹; ¹H nmr (DMSO-d₆): \delta 9.62 (s, 1H, NH), 7.70 (s, 1H, ArH), 7.48–7.46 (m, 2H, ArH), 7.42 (d, 2H,** *J* **= 8.8 Hz, ArH), 7.37 (d, 2H,** *J* **= 8.8 Hz, ArH), 5.21 (d, 1H,** *J* **= 3.6 Hz, ⁵CH), 3.94–3.90 (m, 1H, ⁴CH), 2.78 (dd, 1H,** *J***₁ = 16.0 Hz,** *J***₂ = 7.2 Hz, ³CH₂), 2.46 (dd, 1H,** *J***₁ = 16.0 Hz,** *J***₂ = 7.2 Hz, ³CH₂).** *Anal.* **Calcd. for C₁₇H₁₂Cl₃NO: C, 57.90; H, 3.43; N, 3.97. Found: C, 57.97; H, 3.31; N, 3.88.**

4-(4-Bromophenyl)-6-(2-chlorophenyl)-3,4-dihydropyridin-2(1*H***)-one (5u). ir (potassium bromide): 3199, 3064, 2880, 2839, 1763, 1729, 1668, 1590, 1489, 1357, 1294, 1074, 1011, 932, 827 cm⁻¹; ¹H nmr (DMSO-d₆): \delta 10.04 (s, 1H, NH), 7.62 (d, 2H,** *J* **= 8.4 Hz, ArH), 7.53 (d, 1H,** *J* **= 8.4 Hz, ArH), 7.32 (dd, 1H,** *J***₁ = 8.6 Hz,** *J***₂ = 2.2 Hz ArH), 7.25 (d, 1H,** *J* **= 8.4 Hz, ArH), 7.07 (dd, 1H,** *J***₁ = 8.4 Hz,** *J***₂ = 2.0 Hz ArH), 7.01–6.98 (m, 2H, ArH), 5.12 (d, 1H,** *J* **= 4.4 Hz, ⁵CH), 3.63–3.35 (m, 1H, ⁴CH), 2.32 (dd, 1H,** *J***₁ = 16.0 Hz,** *J***₂ = 7.2 Hz, ³CH₂).** *Anal.* **Calcd. for C₁₇H₁₃BrClNO: C, 56.30; H, 3.61; N, 3.86. Found: C, 56.43; H, 3.52; N, 3.77.**

General Procedure for the Reaction of 2,4,6-triaryl pyridine (6). All reactions were performed in a monomodal EmrysTM Creator from Personal Chemistry, Uppsala, Sweden. Typically, in a 10-mL EmrysTM reaction vial, the appropriate the starting-materials 3 (2 mmol), aromatic ketone (2 mmol), ammonium acetate (1.0 g) were mixed and then capped. The mixture was irradiated at 200 W at 100 °C for 3–6 min (the reaction was monitored by TLC). The reaction mixture was cooled to room temperature and filtered to afford the crude products. The crude products were purified by recrystallization from ethanol.

4-(2-Chlorophenyl)-2,6-bis(3-nitrophenyl)pyridine (6a). ir (potassium bromide): 3085, 1699, 1603, 1524, 1488, 1437, 1351, 884, 807, 750, 733 cm⁻¹; ¹H nmr (DMSO-d₆): δ 9.10 (s, 2H, Pyridyl-H), 8.76 (d, 2H, *J* = 8.0 Hz, ArH), 8.37 (dd, 2H, *J*₁ = 8.0 Hz, *J*₂ = 1.6 Hz, ArH), 8.34 (s, 2H, ArH), 7.88 (t, 2H, *J* = 8.0 Hz, ArH), 7.75–7.70 (m, 2H, ArH), 7.58–7.56 (m, 2H, ArH). *Anal.* Calcd. for C₂₃H₁₄ClN₃O₄: C, 63.97; H, 3.27; N, 9.73. Found: C, 64.03; H, 3.22; N, 9.65.

4-(4-Methylphenyl)-2,6-bis(3-nitrophenyl)pyridine (6b). ir (potassium bromide): 3090, 1602, 1529, 1445, 1345, 880, 823, 804, 709 cm⁻¹; ¹H nmr (DMSO-d₆): δ 9.14 (s, 2H, Pyridyl-H), 8.82 (d, 2H, *J* = 8.0 Hz, ArH), 8.48 (s, 2H, ArH), 8.36 (d, 2H, *J* = 8.4 Hz, ArH), 8.08 (d, 2H, *J* = 8.0 Hz, ArH), 7.88 (t, 2H, *J* = 8.0 Hz, ArH), 7.42 (d, 2H, *J* = 7.6 Hz, ArH), 2.43 (s, 3H, CH₃). *Anal.* Calcd. for C₂₄H₁₇N₃O₄: C, 70.07; H, 4.16; N, 10.21. Found: C, 71.06; H, 4.08; N, 10.18.

4-(4-Bromophenyl)-2,6-bis(4-methoxyphenyl)pyridine (**6c**). ir (potassium bromide): 3082, 1605, 1577, 1540, 1490, 1459, 1423, 1384, 1361, 819 cm⁻¹; ¹H nmr (DMSO-d₆): δ 8.27 (d, 2H, *J* = 8.0Hz, ArH), 8.06 (s, 2H, Pyridyl-H), 8.00 (d, 2H, *J* = 8.0Hz, ArH), 7.75 (d, 2H, *J* = 8.0Hz, ArH), 7.08 (d, 2H, *J* = 8.0Hz, ArH), 3.85 (s, 6H, 2 × OCH₃). *Anal*. Calcd. for C₂₅H₂₀BrNO₂: C, 67.27; H, 4.52; N, 3.14. Found: C, 67.35; H, 4.48; N, 3.16.

4-(2,4-Dichlorophenyl)-2,6-bis(2,4-dichlorophenyl)pyridine (**6d**). ir (potassium bromide): 3080, 1596, 1554, 1536, 1471, 1414, 1363, 1052, 869, 816 cm⁻¹; ¹H nmr (DMSO-d₆): δ 7.88 (s, 2H, Pyridyl-H), 7.76–7.84 (m, 4H, ArH), 7.72–7.50 (m, 1H, ArH), 7.70–7.66 (m, 1H, ArH), 7.52–7.63 (m, 3H, ArH). *Anal.* Calcd. for $C_{23}H_{11}Cl_6N$: C, 53.74; H, 2.16; N, 2.72. Found: C, 53.88; H, 2.08; N, 2.75.

Acknowledgement. We thank for the National Natural Science Foundation of China (No. 20672090), the Nature Science Foundation of the Jiangsu Province (No. BK2006033) and the Key Lab of Biotechnology for Medicinal Plants of Jiangsu Province (01AXL 14) for financial support.

REFERENCES

[1] (a) Scriven, E. F. V. Pyridines and their Benzo Derivatives: (ii) Reactivity at Ring Atoms, In *Comprehensive Heterocyclic Chemistry*, Vol. 2; Katritzky, A. R.; Rees, C. W. Eds., Pergamon Press, Ltd., Oxford, 1984, 165. (b) Uff, B. C. Pyridines and their Benzo Derivatives: (iii) Reactivity of Substituents, In *Comprehensive Heterocyclic Chemistry*, Vol. 2; Katritzky, A. R. Rees, C. W. Eds., Pergamon Press Ltd., Oxford, 1984, 315.

[2] (a) Schultz, A. G. Chem. Rev. 1973, 73, 385. (b) Strumberg, D.; Pommier, Y.; Paull, K.; Jayaraman, M.; Nagafuji, P.; Cushman, M. J. Med. Chem. 1999, 42, 446. (c) Dallavalle, S.; Ferrari, A.; Biasotti, B.; Merlini, L.; Penco, S.; Gallo, G.; Marzi, M.; Tinti, M. O.; Martinelli, R.; Pisano, C.; Carminati, P.; Carenini, N.; Bretta, G.; Perego, P.; De Cearae, M.; Zunino, F. J. Med. Chem. 2001, 44, 3264. (d) Jayaraman, M.; Fox, B. M.; Hollingshead, M.; Kohlagen, G.; Pommier, Y.; Cushman, M. J. Med. Chem. 2002, 45, 242.

[3] (a) Bondavalli, F.; Bruno, O.; Presti, E. L.; Menozzi, G.;
Mosti, L. Synthesis, 1999, 1169. (b) Carles, L.; Narkunan, K.;
Penlou, S.; Rousset, L.; Bouchu, D.; Ciufolini, M. A. J. Org. Chem.
2002, 67, 4304. (c) Schimizu, M.; Ogura, K.; Hachiya, I. Org. Lett.
2003, 4, 2755. (d) Lin, C. H.; Tsai, M. R.; Wang, Y. S.; Chang, N.
C. J. Org. Chem. 2003, 68, 5688. (e) Sutherland, A.; Gallagher, T. J.
Org. Chem. 2003, 68, 3352. (f) Collins, L.; Moyes, C.; Davey, W.
B.; Rowley, M.; Bromidge, F. A.; Quirk, K.; Atack, J. R.;
Mckernan, R. M.; Thompson, S. -A.; Wafford, K.; Dawson, G. R.;
Pike, A.; Sohal, B.; Tsou, N. N.; Ball, R. G.; Castro, J. L. J. Med.
Chem. 2002, 45, 1887.

[4] (a) Dorigo, D.; Fraccarollo, D.; Gaion, R. M.; Santostasi,
G.; Borea, P. A.; Floreani, M.; Mosti, L.; Maragno, I. Gen. Pharmac. 1997, 28, 781. (b) Calter, M. A.; Guo, X. J. Org. Chem.
1998, 63, 5308. (c) Arraya's, R. G.; Alcudia, A.; Liebeskind, L. S. Org. Lett. 2001, 3, 3381. (d) Dziedzic, M.; Małecka, M.; Furman, B.
Org. Lett. 2005, 7, 1725. (e) El-Kemary, M.; Organero, J. A.; Douhal, A. J. Med. Chem. 2006, 49, 3086. (f) Irlapati, N. R.; Baldwin, J. E.; Adlington, R. M.; Pritchard, G. J. Org. Lett. 2003, 5, 2351.

[5] Labaudiniere, R.; Dereu, N.; Cavy, F.; Guillet, M. C.; Marquis, O.; Terlain, B. *J. Med. Chem.* **1992**, *35*, 4315.

[6] Wang, S. Z.; Pan, J.; Hu, Y. F.; Hu, H. W. Synthesis, 2005, 5, pp 753-756.

[7] (a) Mckillop, A.; Boulton, A. J. In *Comprehensive Heterocyclic Chemistry*, Vol. 2; Katritzky, A. R.; Rees, C. W. Eds., Pergamon: New York, 1984, Part 2A, 67. (b) Mckillop, A.; Boulton, A. J. In *Comprehensive Heterocyclic Chemistry*, Vol. 2; Katritzky, A. R.; Rees, C. W. Eds., Pergamon: New York, 1984, Part 2A, 395.

[8] Katritzsky, A. R.; Belayakov, S. A.; Sorochinski, A. E.;
 Henderson, S. A. J. Chen, J. Org. Chem. 1997, 62, 6210.

[9] Thesing, J.; Muller, A. Chem. Ber. 1957, 90, 711.

[10] (a) Besidsky, Y.; Luthman, K.; Claesson, A.; Fowler, C. J.; Csoregh, I.; Hacksell, U. J. Chem. Soc., Perkin Trans. I **1995** 465. (b) Katoh, A.; Kitamura, Y.; Fujii, H.; Horie, Y.; Satoh, T.; Ohkanda, J.; Yokomori, Y. Heterocycles, **1998**, 49, 280. (c) Grosche, P.; Holtzel, A.; Walk, T. B.; Trautwein, A. W.; Jung, G. Synthesis, **1999**, 1961.

[11] Wang, S. Z.; Yu, G.; Lu, J.; Xiao, K.; Hu, Y. F.; Hu, H. W. *Synthesis*, **2003**, *4*, 487.

[12] (a) Jones, T. H.; Blum, M. S. In Alkaloids: Chemical and Biological Perspectives. Vol. 1; Pelletier, S. W. Ed, Wiley: New York, 1985, 33-84. (b) Jones, T. H.; Blum, M. S. In Alkaloids: Chemical and Biological Perspectives. Vol. 3; Pelletier, S. W. Ed, Wiley: New York, 1985, 1-90. (c) Daly, J. W. J. Nat. Prod. **1998**, 61, 162. (d) Plunkett, A. O. Nat. Prod. Rep. **1994**, 11, 581. (e) Rubiralta, M.; Giralt, E.; Diez, A. In Piperidine: Structure, Preparation, Reactivity and Synthetic Applications of Piperidine and its derivatives. **Amsterdam**, **1991**.

[13] Paulvannan, K.; Chen, T. J. Org. Chem. 2000, 65, 6160.

[14] Creswell, M. W.; Bolton, G. L.; Hodges, J. C.; Meppen, M. *Tetrahedron*, **1998**, *54*, 3983.

[15] Bigi, F.; Carloni, S.; Ferrari, L.; Maggi, R.; Mazzacani, A.; Sartori, G. *Tetrahedron Lett.* **2001**, *42*, 5203.

[16] Perlmutter, P. Conjugate Addition Reactions in Organic Synthesis, In Tetrahedron Organic Chemistry Series. Vol 9; Baldwin, J. E.; Magnus, P. D. Ed. Pergamon Press: Oxford, 1992.

[17] Tu, S. J.; Li, T. J.; Shi, F.; Wang, Q.; Zhang, J. P.; Xu, J. N.; Zhu, X. T.; Zhang, X. J. Synthesis, **2005**, *18*, 3045.

[18] Crystal data for 5f: Empirical formula $C_{17}H_{13}FN_2O_3$, Mr = 312.29, T = 294(2) K, Monoclinic, space group P2(1)/c, a = 13.960(3) Å, b = 8.5633(18) Å, c = 12.523(3) Å, $\alpha = 90^{\circ}$, $\beta = 103.789(4)^{\circ}$, $\gamma = 90^{\circ}$, V = 1453.9(5) Å³, Z = 4, Dc = 1.427 Mg/cm³, λ (MoK α) = 0.71073 Å, μ = 0.108 mm⁻¹, F(000) = 648, 1.50°< θ <26.39°, R = 0.0443, wR₂ = 0.0970, S = 0.989, Largest diff. Peak and hole: 0.160 and -0.189 e/Å³.